Papers
5
Total Citations
22
H-Index
3
About
Gal Wald is a rising urologic surgeon-scientist whose research centers on optimizing surgical outcomes and cost-efficiency in robotic-assisted urologic oncology. His work spans two key areas: advancing same-day discharge protocols for kidney cancer surgery and refining nerve-sparing techniques for prostate cancer patients. In a landmark 2024 study (10 citations), Wald demonstrated that same-day discharge after robotic partial and radical nephrectomy is both safe and cost-effective, challenging traditional inpatient recovery models. He further validated this approach in a multi-institutional 2025 analysis (4 citations), showing broad clinical applicability. On the prostate cancer front, Wald pioneered the posterior approach to endopelvic neurovascular total sparing (PATENTS) during robotic-assisted radical prostatectomy, which significantly improves erectile function recovery (3 citations). He also led a multicenter comparison identifying factors that enhance urinary continence recovery after pelvic fascia-sparing prostatectomy (3 citations). His economic analyses reveal that robotic nephrectomy achieves cost advantages over laparoscopic approaches through economies of scale (2 citations). With over 20 citations across his early-career publications, Wald is shaping the future of value-based, patient-centered urologic surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5